Vaxcyte, Inc. — Director's Dealing 2021

Mar 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-03-15

Reporting Person: Wright-Mitchell Jane (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-15	Common Stock	M	2500	$2.03	Acquired	4062	Direct
2021-03-15	Common Stock	S	1013	$27.01	Disposed	3049	Direct
2021-03-15	Common Stock	S	1487	$27.49	Disposed	1562	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-15	Stock Option (right to buy)	$2.03	M	2500	Disposed	2029-03-20	Common Stock (2500)	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The price reported is a weighted-average price. The shares were sold at prices ranging from $26.28 to $27.27. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: The price reported is a weighted-average price. The shares were sold at prices ranging from $27.355 to $27.73. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: 1/4 of the shares subject to the option vested on January 7, 2020, and 1/48 of the shares vest monthly thereafter.